Form D · Biotechnology
Genialis, Inc.
Boston, MA · CIK 0001948756
Offering snapshot reported Dec 31, 2025 · SEC filing
- Reported sold
- $700K Offering amount: $3M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 17, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 31, 2025 | Initial | $700,000 | No comparison | 2 | SEC filing |
| Jan 31, 2023 | Initial | $11,423,253 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-568631
Source: Form D, filed Dec 31, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Hamzeh Abdul Hadi | Director |
| Luka Ausec | Executive |
| Nadine Geiser | Director |
| Tjasa Krisper Kutin | Executive |
| Ita Lu | Director |
| Krista Mc Kerracher | Director |
| Cedric Hermann Odje | Director |
| Rafael Rosengarten | Director, Executive |
| Miha Stajdohar | Director, Executive |
| Elia Stupka | Director |
| Drew Volpe | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
68 Harrison Ave #605 Pmb 29417
Boston, MA, 02111
Boston, MA, 02111